A Phase I Safety and Tolerability Study of Vorinostat in Combination With Sorafenib in Patients With Advanced Solid Tumors, With Exploration of Two Tumor-Type Specific Expanded Cohorts at the Recommended Phase 2 Dose (Renal Cell Carcinoma and Non-Small Ce
| City: |
|
Aurora |
| State: |
|
Colorado |
| Zip Code: |
|
80045 |
| Conditions: |
|
Advanced Solid Tumors |
| Purpose: |
|
The main purpose of this study is to:
- Evaluate the safety of vorinostat in combination with sorafenib.
- Determine the largest dose of vorinostat + sorafenib that can be given safely to
humans.
- Determine if vorinostat + sorafenib are effective in stopping tumors from growing or in
decreasing their size.
- Study the side effects of vorinostat + sorafenib.
|
| Study Summary: |
|
|
| Criteria: |
|
Eligibility criteria include but are not limited to:
- 18 years or older with advanced solid tumor(s),
- Renal cell or non-small cell lung cancer.
|
| NCT ID: |
|
NCT00635791 |
| Primary Contact: |
|
Principal Investigator
David R Camidge, MD
University of Colorado, Denver
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Aurora, Colorado 80045
United States
Stacy Grolnic
Phone: 720-848-0655
Email: stacy.grolnic@ucdenver.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 23, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|